Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed And/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies

Treatment with regimens containing pomalidomide may be an option for patients with relapsed and/or refractory multiple myeloma (RRMM) progressing on or previously refractory to lenalidomide. The triplet combination of carfilzomib, pomalidomide and dexamethasone (KPd) has been shown to be well-tolerated and active in RRMM in two phase 1/2 studies (NCT01665794 [n=65], NCT01464034 [n=118]); however, both studies were single arm with a relatively small number of enrolled patients. A pooled analysis of individual patient data would provide an overall assessment of clinical outcomes for KPd. This meta-analysis will assess the efficacy and safety of KPd in RRMM.